4D Molecular Therapeutics Files Definitive Proxy Statement
Ticker: FDMT · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
4D Molecular Therapeutics filed its proxy statement for the June 17, 2025 meeting. Vote your shares!
AI Summary
4D Molecular Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 17, 2025. The filing outlines the company's governance and proposals to be voted on by shareholders, including the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, executive pay, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine filing of a proxy statement, providing information to shareholders without introducing new financial risks.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- April 29, 2025 (date) — Filing Date
- June 17, 2025 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for an upcoming shareholder meeting, detailing matters to be voted upon.
When is the shareholder meeting for 4D Molecular Therapeutics?
The shareholder meeting is scheduled for June 17, 2025.
Who is the filer of this proxy statement?
The filer is 4D Molecular Therapeutics, Inc., as specified in its charter.
What is the filing date of this document?
This Definitive Proxy Statement was filed on April 29, 2025.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for 4D Molecular Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding 4D Molecular Therapeutics, Inc. (FDMT).